Dr. Jones discusses clinical fracture incidence in mHSPC
In this podcast, Prof. Igor Tsaur (DE), chief editor of the UROONCO PCa editorial board talks with Dr. Craig Jones (GB), from Salford Royal and Christie Hospitals, about his recent presentation at AUA2023, "Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (ADT) with or without docetaxel (Doc): Long-term results of two phase 3 trials from the STAMPEDE platform proto...